NICE recommend venetoclax and azacitidine for patients with aggressive blood cancer

Pharma Times

16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive.

NICE have published a positive final appraisal document recommending routine NHS use of Venclyxto (venetoclax) with azacitidine for the treatment of aggressive blood cancer acute myeloid leukaemia.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder